Abstract
The binding of CPT-11 and SN-38 to human plasma proteinswas studied by ultrafiltration at 37°C and pH 7.4. In plasma,CPT-11 was 66–60% bound in the range 100–4000ng/ml and SN-38 was 94–96% bound in the range50–200 ng/ml. At these concentrations the plasma bindingof CPT-11 was slightly saturable, but the plasma binding of SN-38was concentration-independent. Albumin was the main carrier ofCPT-11 and SN-38 in plasma. In blood, the binding of CPT-11 wasmoderate (80%), mainly to plasma proteins (47%) anderythrocytes (33%). The binding of SN-38 was high(99%) and most of SN-38 in blood was located in bloodcells (approximately 66%) The simulation of a grade 3hematotoxicity (according to National Cancer Institute's CommonToxicity Criteria grading) on the SN-38 blood distributionyielded an increase in fu (free fraction of drug in plasma) from1.05 to 2.08 and a decrease in CBl/CP from1.66 to 1.14 (both resulting from a decreased cellbinding).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
O'Reilly S, Rowinsky EK: The clinical status of irinotecan (CPT11), a novel water soluble camptothecin analogue. Crit Rev Oncol Hematol 24: 47-70, 1996
Urien S, Barré J, Morin C, Paccaly A, Montay G, Tillement JP: Docetaxel serum protein binding with high affinity to alpha1-glycoprotein acid. Invest New Drugs 14: 147-151, 1996
Bruno R, Hile D, Riva A, Vivier N, Bokkel Huinnink WW, Oosterom AT, Kaye SE, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevalier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB: Population pharmacokinet ics/pharmacodynamics of Docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187-196, 1998
Havel RJ, Eder HA, Bragdon JM: The distribution and chemical composition of ultracentrifugally separated lipoproteins in plasma. J Clin Invest 34: 1345-1354, 1955
Urien S, Brée F, Breillout F, Krikorian A, Tillement JP: Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood. Cancer Chemother Pharmacol 32: 231-234, 1993
Urien S, Riant P, Renouard A, Coulomb A, Rocher I, Tillement JP: Binding of indapamide to plasma proteins and erythrocytes. Biochem Pharmacol 37: 2963-2966, 1988
Burke TG, Mi Z: The structural basis of comptothecin interactions with human serum albumin: Impact on drug stability. J Med Chem 37: 40-46, 1994
Mi Z, Burke TG: Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. Biochemistry 33: 12540-12545, 1994
Tillement JP, Houin G, Zini R, Urien S, Albengres E, Barré J, Lecomte M, D'Athis P, Sébille B: The binding of drugs to biological macromolecules in serum. Recent advances and therapeutic significance. Adv Drug Res 13: 59-94, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Combes, O., Barré, J., Duché, JC. et al. In Vitro Binding and Partitioning of Irinotecan (CPT-11) and its Metabolite, SN-38, in Human Blood. Invest New Drugs 18, 1–5 (2000). https://doi.org/10.1023/A:1006379730137
Issue Date:
DOI: https://doi.org/10.1023/A:1006379730137